Plain-English translation of NCT03839862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why some patients with spondyloarthropathy respond well to TNF-inhibitor medications while others don't. This study will compare the gut bacteria of patients whose symptoms improve with to those whose symptoms don't improve, looking for differences that might explain why the medication works better for some people.
Right now, doctors don't fully understand why this medication helps some patients but not others. Recent research suggests that the bacteria living in your gut may play a role in how your body responds to treatment, so this study is exploring that connection.
You likely qualify if…
You likely don't qualify if…
You would be part of the study's routine clinic care at Skane University Hospital in Sweden. You'll provide stool and blood samples at two time points and have your disease activity checked during regular clinical visits. Researchers will then analyze your gut bacteria samples and compare them to your treatment response to see if there's a connection.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Sweden
Enrollment target
~50 participants
Started
January 2019
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kristofer Andréasson, MD PhD
Lund University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.